Overview

Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer

Status:
Terminated
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether weekly paclitaxel followed by weekly doxorubicin plus daily oral cyclophosphamide without granulocyte colony-stimulating factor (G-CSF) is feasible in the treatment of locally advanced HER2-negative breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Instituto do Cancer do Estado de São Paulo
Collaborator:
Fundação Faculdade de Medicina
Treatments:
Albumin-Bound Paclitaxel
Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Paclitaxel